Share your experience of delivering bispecific antibodies for the development of a BSH good practice paper

Maddie Dichiu
Published:
Sign up to join the conversation

As bispecific treatments are rolled out across the NHS, a team including Myeloma UK’s Principal Researcher in Applied Health Research, Dr Sandra Quinn, is working on developing a British Society for Haematology (BSH) good practice paper. The guidelines will focus on delivery of bispecific antibodies in the UK.

The team delivering this work are seeking input from clinical teams across the UK about their experiences delivering bispecific antibody treatments to myeloma patients, and any barriers and facilitators they encounter.

The group are aware of varied practices in the delivery of these bispecific antibodies and are in the process of developing best practice guidelines for these treatments to support healthcare teams optimise patient care and treatment access across the UK.

By completing this short survey, you can contribute to the understanding of current practices and inform guidance to overcome current challenges in the delivery of this new treatment pathway.

Complete the survey

Any healthcare professional involved in the care of patients receiving bispecific antibodies is invited to participate, including:

  • Haematologists
  • Virologists
  • Microbiologists
  • Nurses
  • Pharmacists

Please share your insights by Friday 20 June 2025.

You might also like